MarketCap
Facebook
X
Telegram
Intra-Cellular Therapies Balance Sheet 2024-2011 | ITCI
Brief overview of Intra-Cellular Therapies's balance sheet structure
This overview follows the five latest available annual observations between 2020 and 2024.
Assets advanced +90.6% to $1.4 billion from $717.3 million; annual growth near 17.5% reflects a fast increase in scale.
Liabilities expanded faster than the asset base, +261.4% versus +90.6%. Debt-service capacity deserves attention.
The equity-to-assets ratio is 84%, compared with 91.6% five periods ago. The balance sheet has a substantial internal cushion.
The balance sheet holds more cash than interest-bearing debt; net debt is -$290 million, indicating minimal leverage.
The cash share moved from 8.4% to 22.5%. A higher figure generally provides more room in an adverse scenario.
The accumulated result is -$1.7 billion and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
Intra-Cellular Therapies retains a reasonably healthy balance sheet structure, which still needs support from earnings and cash flow.
Annual Balance Sheet Intra-Cellular Therapies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-290 M | -131 M | -129 M | -67 M | - | -84.5 M | -54.9 M | -37.8 M | -48.6 M | -47.2 M | -61.3 M | 26.2 M | -19.1 M | - |
Long Term Debt |
12.7 M | 13.3 M | 15.5 M | 18.7 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
4.23 M | 3.61 M | 4.57 M | 6.73 M | 5.54 M | 3.19 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 20 M | 3.19 M | 2.84 M | 2.87 M | 1.6 M | - | - | - | - |
Total Current Liabilities |
206 M | 124 M | 83.2 M | 53.4 M | 36.9 M | 36.2 M | 36.3 M | 14.2 M | 10.5 M | 6.26 M | 10.6 M | 6.83 M | - | - |
Total Liabilities |
218 M | 137 M | 98.7 M | 72 M | 60.5 M | 56.2 M | 39.5 M | 17 M | 13.4 M | 7.86 M | 10.6 M | 26.2 K | 2.84 M | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | 1.67 M | - |
Retained Earnings |
-1.69 B | -1.62 B | -1.48 B | -1.22 B | -937 M | -710 M | -562 M | -407 M | -309 M | -193 M | -88.3 M | -32.1 K | -30.7 M | - |
Total Assets |
1.37 B | 728 M | 755 M | 490 M | 717 M | 251 M | 357 M | 471 M | 389 M | 484 M | 131 M | 4.07 K | 19.8 M | - |
Cash and Cash Equivalents |
307 M | 148 M | 149 M | 92.4 M | 60 M | 108 M | 54.9 M | 37.8 M | 48.6 M | 47.2 M | 61.3 M | 35.2 M | 15.6 M | 13.7 M |
Book Value |
1.15 B | 591 M | 656 M | 418 M | 657 M | 195 M | 318 M | 454 M | 376 M | 476 M | 121 M | -22.1 K | 17 M | - |
Total Shareholders Equity |
1.15 B | 591 M | 656 M | 418 M | 657 M | 195 M | 318 M | 454 M | 376 M | 476 M | 121 M | 31.6 M | 17 M | 17.9 M |
All numbers in USD currency
Quarterly Balance Sheet Intra-Cellular Therapies
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
13.5 M | 14.1 M | 12.7 M | 13.3 M | 13.9 M | 14.4 M | 15 M | 15.5 M | 19.2 M | 19.1 M | 16.8 M | 18.7 M | 20.3 M | 21.7 M | 22.6 M | 23.6 M | 23.9 M | 21.2 M | 19.7 M | 20 M | 20.3 M | 20.6 M | 20.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.88 M | 2.91 M | 2.95 M | 2.87 M | 2.56 M | 2.26 M | 1.97 M | 1.6 M | - | 1.6 M | 160 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
180 M | 176 M | 148 M | 137 M | 117 M | 107 M | 94.5 M | 98.7 M | 96.6 M | 89.7 M | 75.8 M | 72 M | 70.2 M | 72.1 M | 62.3 M | 60.5 M | 61.9 M | 61.4 M | 50.8 M | 56.2 M | 53.6 M | 53.1 M | 54.4 M | 39.5 M | 32 M | 21.7 M | 22.5 M | 17 M | 14.8 M | 9.87 M | 19.3 M | 13.4 M | 143 M | 21.6 M | 10.9 M | 7.86 M | 11.3 M | 9.84 M | 14.8 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 417 K | - | - | 1.67 M | 1.67 M | - | - | - | - | - | - |
Retained Earnings |
-1.67 B | -1.65 B | -1.63 B | -1.62 B | -1.59 B | -1.56 B | -1.52 B | -1.48 B | -1.43 B | -1.38 B | -1.29 B | -1.22 B | -1.14 B | -1.06 B | -990 M | -937 M | -876 M | -821 M | -758 M | -710 M | -670 M | -635 M | -597 M | -562 M | -522 M | -480 M | -443 M | -407 M | -377 M | -354 M | -336 M | -309 M | -282 M | -252 M | -221 M | -193 M | -164 M | -132 M | -111 M | -88.3 M | -73.1 M | -66.6 M | -62.1 M | -57.6 M | -49.5 M | -57.6 M | -57.6 M | -30.7 M | -30.7 M | - | - | - | - | - | - |
Total Assets |
1.32 B | 1.32 B | 747 M | 728 M | 718 M | 714 M | 722 M | 755 M | 782 M | 812 M | 869 M | 490 M | 557 M | 626 M | 674 M | 717 M | 771 M | 441 M | 481 M | 251 M | 281 M | 310 M | 343 M | 357 M | 386 M | 412 M | 446 M | 471 M | 334 M | 350 M | 372 M | 389 M | 543 M | 448 M | 464 M | 484 M | 513 M | 213 M | 237 M | 131 M | 138 M | 141 M | 147 M | 38.4 M | 47.3 M | 38.4 M | 49 | 19.8 M | 19.8 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
464 M | 693 M | 140 M | 148 M | 99.4 M | 142 M | 75.7 M | 149 M | 135 M | 77.2 M | 129 M | 92.4 M | 106 M | 121 M | 130 M | 61.4 M | 301 M | 129 M | 180 M | 108 M | 102 M | 91.8 M | 64.1 M | 54.9 M | 69.8 M | 69.8 M | 74.4 M | 37.8 M | 52.3 M | 29.6 M | 23.6 M | 48.6 M | 200 M | 52 M | 37.2 M | 47.2 M | 333 M | 71.4 M | 101 M | 61.3 M | 68.9 M | 91.1 M | 144 M | 35.2 M | 44.1 M | 35.2 M | 49 | 15.6 M | 15.6 M | - | - | 13.7 M | - | - | - |
Book Value |
1.14 B | 1.14 B | 599 M | 591 M | 601 M | 607 M | 628 M | 656 M | 685 M | 722 M | 793 M | 418 M | 487 M | 554 M | 612 M | 657 M | 709 M | 380 M | 430 M | 195 M | 227 M | 257 M | 289 M | 318 M | 354 M | 390 M | 423 M | 454 M | 319 M | 340 M | 353 M | 376 M | 399 M | 426 M | 453 M | 476 M | 502 M | 204 M | 222 M | 121 M | 127 M | 131 M | 136 M | 38.4 M | 47.3 M | 38.4 M | 49 | 19.8 M | 19.8 M | - | - | - | - | - | - |
Total Shareholders Equity |
1.14 B | 1.14 B | 599 M | 591 M | 601 M | 607 M | 628 M | 656 M | 685 M | 722 M | 793 M | 418 M | 487 M | 554 M | 612 M | 657 M | 709 M | 380 M | 430 M | 195 M | 227 M | 257 M | 289 M | 318 M | 354 M | 390 M | 423 M | 454 M | 319 M | 340 M | 353 M | 376 M | 399 M | 426 M | 453 M | 476 M | 502 M | 204 M | 222 M | 121 M | 134 M | 139 M | 143 M | 31.6 M | 39.6 M | 31.6 M | -33 K | 17 M | 17 M | - | - | 17.9 M | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Intra-Cellular Therapies, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
